Summarized by Masters of Longevity from M Ventures.
The financing supports drug–software combination treatments and planned Phase 3 development of Hybridopa for Parkinson’s disease.
Key Takeaways
- Proceeds were intended to fund global Phase 3 development of Hybridopa.
- The round brought Remepy’s total capital raised to $62 million.
- Hybridopa remained investigational and was not approved by the FDA.
